{
  "title": "Atopic Dermatitis Management",
  "specialty": "dermatology",
  "contentId": "atopic-dermatitis",
  "setting": "outpatient",
  "frequency": "high",
  "mortality": "low",
  "keywords": ["atopic dermatitis", "eczema", "allergic dermatitis", "pediatric dermatology", "topical corticosteroids", "dupilumab"],
  "description": "Comprehensive management guide for atopic dermatitis including diagnosis, treatment protocols, and long-term care strategies for pediatric and adult patients.",
  "author": "JP Silva",
  "lastUpdated": "2024-12-27",
  "reviewDate": "2025-06-27",
  "status": "published",
  "clinicalSettings": ["outpatient", "pediatric", "allergy clinic"],
  "ageGroups": ["pediatric", "adult", "elderly"],
  "associatedConditions": [
    "allergic rhinitis",
    "asthma",
    "food allergies",
    "contact dermatitis"
  ],
  "diagnosticCriteria": {
    "source": "Hanifin and Rajka Criteria",
    "majorFeatures": 4,
    "minorFeatures": 23,
    "requiredMajor": 3,
    "requiredMinor": 3
  },
  "treatmentProtocols": {
    "topical": {
      "firstLine": [
        "topical corticosteroids",
        "calcineurin inhibitors",
        "moisturizers"
      ],
      "potencyGuide": {
        "mild": "hydrocortisone 1-2.5%",
        "medium": "triamcinolone 0.1%",
        "high": "fluocinonide 0.05%"
      }
    },
    "systemic": {
      "biologics": ["dupilumab", "tralokinumab"],
      "jakInhibitors": ["upadacitinib", "abrocitinib"],
      "traditional": ["methotrexate", "cyclosporine", "azathioprine"]
    },
    "maintenance": {
      "proactive": "intermittent anti-inflammatory",
      "reactive": "treat flares only",
      "skinBarrier": "daily moisturizing"
    }
  },
  "severityScales": [
    {
      "name": "EASI",
      "fullName": "Eczema Area and Severity Index",
      "range": "0-72",
      "interpretation": {
        "mild": "0-7",
        "moderate": "7.1-21",
        "severe": "21.1-50",
        "verySevere": ">50"
      }
    },
    {
      "name": "SCORAD",
      "fullName": "Scoring Atopic Dermatitis",
      "range": "0-103",
      "components": ["extent", "intensity", "subjective symptoms"]
    }
  ],
  "complications": {
    "infectious": [
      "secondary bacterial infection",
      "eczema herpeticum",
      "molluscum contagiosum"
    ],
    "other": [
      "contact sensitization",
      "psychological impact",
      "sleep disturbance"
    ]
  },
  "monitoringSchedule": {
    "newPatients": "2-4 weeks",
    "stableDisease": "3-6 months",
    "systemicTherapy": "monthly initially, then quarterly",
    "flareManagement": "1-2 weeks"
  },
  "qualityMetrics": {
    "evidenceLevel": "A",
    "guidelineCompliance": "AAD/EADV",
    "lastReview": "2024-12-27",
    "outcomesMeasured": ["EASI", "DLQI", "patient satisfaction"]
  },
  "relatedContent": [
    "contact-dermatitis",
    "pediatric-dermatology",
    "allergen-testing",
    "topical-corticosteroid-guidelines"
  ],
  "interactiveTools": [
    "easi-calculator",
    "scorad-assessment",
    "treatment-selection-guide",
    "patient-symptom-tracker"
  ],
  "presentationPath": "presentations/dermatology/atopic-dermatitis.html",
  "patientEducation": {
    "handouts": [
      "skincare-routine",
      "trigger-avoidance",
      "medication-application-guide"
    ],
    "videos": [
      "proper-moisturizer-application",
      "topical-medication-technique"
    ]
  },
  "referralCriteria": {
    "allergy": ["suspected food allergies", "severe environmental triggers"],
    "dermatology": ["refractory cases", "systemic therapy consideration"],
    "psychiatry": ["significant psychological impact", "sleep disturbance"]
  },
  "costConsiderations": {
    "firstLine": "low-moderate",
    "biologics": "high",
    "jakInhibitors": "high",
    "genericOptions": ["hydrocortisone", "triamcinolone", "tacrolimus"]
  },
  "additionalResources": {
    "guidelines": [
      "https://www.aad.org/",
      "https://www.eadv.org/"
    ],
    "patientOrganizations": [
      "National Eczema Association",
      "Global Parents for Eczema Research"
    ]
  }
}